Metformin, arterial function, intima-media thickness and nitroxidation in metabolic syndrome: The mefisto study

Clinical and Experimental Pharmacology and Physiology

Volumn 35, Issue 8, 2008, Pages 895-903

  Meaney, Eduardo ^a   Vela, Agustín ^a   Samaniego, Virginia ^a   Meaney, Alejandra ^a   Asbún, Juan ^b   Zempoalteca, Juan Carlos ^b   Elisa, Zárate N ^b   Emma, Mendoza N ^a   Guzman, Martin ^c   Hicks, Juan ^c   Ceballos, Guillermo ^b,d  

^a CENTRO MÉDICO NACIONAL 20 DE NOVIEMBRE   (Mexico)

^b INSTITUTO POLITÉCNICO NACIONAL   (Mexico)

^c INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^d HOSPITAL REGIONAL 1 DE OCTUBRE   (Mexico)

Author keywords

Arterial stiffness; Intima media thickness; Metabolic syndrome; Metformin; Nitroxidation

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; ANGIOTENSIN II ANTAGONIST; C REACTIVE PROTEIN; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; METFORMIN; NITRIC OXIDE; TRIACYLGLYCEROL;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OXIDATIVE STRESS; PATIENT COUNSELING; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADULT; ARGININE; CAROTID ARTERIES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC SYNDROME X; METFORMIN; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; OXIDATIVE STRESS; TUNICA INTIMA;

EID: 46749120271     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2008.04920.x     Document Type: Article

References (79)

1. Caterson ID, Hubbard V, Bray GA et al. Obesity, a worldwide epidemic related to heart disease and stroke: Group III. Worldwide comorbidities of obesity. Circulation 2004 110 : 476 86.
2. Sánchez-Castillo CP, Velázquez-Monroy O, Lara-Esqueda A et al. Diabetes and hypertension increases in a society with abdominal obesity: Results of the Mexican National Health Survey 2000. Public Health Nutr. 2004 8 : 53 60.
3. Doelle GC. The clinical picture of metabolic syndrome. An update on this complex of conditions and risk factors. Postgrad. Med. 2004 116 : 30 2.
4. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J. Clin. Endocrinol. Metab. 2001 86 : 713 18.
5. Haffner SM, Cassells HB. Metabolic syndrome: A new risk factor of coronary heart disease. Diabetes Obes. Metab. 2003 5 : 359 70.
6. Murphy NF, MacIntyre K, Stewart S, Hart CL, Hole D, McMurray JJV. Long-term cardiovascular consequences of obesity: 20 years follow-up of more than 15 000 middle-aged men and women (the Renfrew-Paisley study). Eur. Heart J. 2006 27 : 96 106.
7. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001 24 : 683 9.
8. Bonow RO, Eckel RH. Diet, obesity, and cardiovascular risk. N. Engl. J. Med. 2003 348 : 2057 8.
9. The DREAM Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: A randomized controlled trial. Lancet 2006 368 : 1096 105.
10. Diabetes Prevention Program Research Group. Effects of withdrawal from metformin on the development of diabetes in the Diabetes Prevention Program. Diabetes Care 2005 326 : 977 9.
11. Nagi DK, Yudkin JS. Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. Diabetes Care 1993 16 : 621 9.
12. Kirpichnikov D, MacFarlane SI, Soers JR. Metformin: An update. Ann. Intern. Med. 2002 137 : 25 33.
13. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome. Systematic review and meta-analysis. BMJ 2003 327 : 951 3.
14. Bellot-Rojas P, Posadas-Sanchez R, Caracas-Portilla N et al. Comparison of metformin versus rosiglitazone in patients with acanthosis nigricans: A pilot study. J. Drugs Dermatol. 2006 5 : 884 9.
15. Hess AM, Sullivan DL. Metformin for prevention of type 2 diabetes. Ann. Pharmacother. 2004 38 : 1283 5.
16. Moghetti P, Castello R, Negri C et al. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J. Clin. Endocrinol. Metab. 2000 85 : 139 46.
17. Hansel B, Giral P, Nobecourt B et al. Metabolic syndrome is associated with elevated oxidative stress and dysfunctional dense high-density lipoprotein particles displaying impaired antioxidative activity. J. Clin. Endocrinol. Metab. 2004 89 : 4963 71.
18. Gomes MB, Cailleaux S, Tibiriçá E. Metformin prevents the impairment of endothelium-dependent vascular relaxation induced by high glucose challenge in rabbit isolated perfused kidneys. Naunyn Schmiedebergs Arch. Pharmacol. 2005 372 : 24 30.
19. Vitale C, Mercuro G, Cornoldi A, Volterrani M, Rosano GMC. Metformin improves endothelial function in patients with metabolic syndrome. J. Intern. Med. 2005 258 : 250 6.
20. Diamanti-Kandarakis E, Paterakis T, Alexandraki K et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Obes. Res. 2003, 1278 89.
21. Caballero AE, Delgado D, Aguilar-Salinas CA et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: A placebo-controlled, randomized clinical trial. J. Clin. Endocrinol. Metab. 2004 89 : 3943 8.
22. Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001 285 : 2486 97.
23. Medina Navarro R, Lifshitz A, Wacher N, Hicks JJ. Changes in human serum antioxidant capacity and peroxidation after four months of exposure to air pollutants. Arch. Med. Res. 1997 28 : 205 8.
24. International Conference on Harmonisation. Guidelines for Good Clinical Practice. International Conference on Harmonisation for Technical Requirements for the Registration of Pharmaceuticals for Human Use. ICH, London. 1996.
25. Carlson MV, Botd KM, Webb DJ. Declaration of Helsinki: Past, present and future. Br. J. Clin. Pharmacol. 2004 57 : 695 713.
26. Ley General de Salud. Reglamento de la ley General de Salud en Materia de Investigacion para la Salud. Title 5, Chapter 1, 1986. http://www.salud.gob.mx/ unidades/cdi/nom/compi/rlgsmis.html
27. Dalle-Done I, Rossi R, Giustarini D, Milzani A, Colombo R. Protein carbonyl groups as biomarkers of oxidative stress. Clin. Chim. Acta 2003 329 : 23 38.
28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951 193 : 265 75.
29. Yagi K. Sample procedure for specific assay of lipid hidroperoxides in serum or plasma. Free Radic. Antioxidant Protocols 1998 108 : 101 6.
30. Lehrer SS, Pasman GD. Ultraviolet irradiation effects in poly-l-tyrosine and model compounds. Identification of bityrosine as a photoproduct. Biochemistry 1967 6 : 757 67.
31. Capeillére-Blandin C, Gausson V, Deschamps-Lastscha B, Witko-Sarsat V. Biochemical and spectrophotometric significance of advance oxidized protein products. Biochim. Biophys. Acta 2004 1689 : 91 102.
32. 15N] nitrate in biological fluids. Anal. Biochem. 1982 126 : 131 8.
33. Rojas-Hernández S, Rodríguez-Monroy MA, Moreno-Fierros L et al. Nitric oxide production and nitric oxide synthase immunoreactivity in Naegleria fowleri. Parasitol Res. 2007 101 : 269 74.
34. del Sol AI, Moons KG, Hollander M et al. Is carotid intima-media thickness useful in cardiovascular disease risk assessment? The Rotterdam Study. Stroke 2001 32 : 1532 8.
35. Meaney E, Soltero E, Samaniego V et al. Vascular dynamics in isolated systolic arterial hypertension. Clin. Cardiol. 1995 18 : 721 5.
36. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003 289 : 2560 72.
37. Alberti KGMM, Zimmet PZ, Shaw JE. The metabolic syndrome: A new world-wide definition from the International Diabetes Federation consensus. Lancet 2005 366 : 1059 62.
38. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005 365 : 1415 28.
39. Caballero AE. Endothelial dysfunction in obesity and insulin resistance: A road to diabetes and heart disease. Obes. Res. 2003 11 : 1278 89.
40. Clapp B, Hingorani A, Kharbanda R et al. Inflammation-induced endothelial dysfunction involves reduced nitric oxide bioavailability and increased oxidant stress. Cardiovasc. Res. 2004 64 : 172 8.
41. Böger RH. Association of asymmetric dimethylarginine and endothelial dysfunction. Clin. Chem. Lab. Med. 2003 41 : 1467 72.
42. Stühlinger MC, Oka RK, Graf EE et al. Endothelial dysfunction induced by hyperhomocyst(e)inemia. Role of asymmetric dimethylarginine. Circulation 2003 108 : 933 8.
43. Festa A, D'Agostino Jr. R, Howard G, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome. The Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000 102 : 42 7.
44. Mark AL. Dietary therapy for obesity is a failure and pharmacotherapy is the future: A point of view. Clin. Exp. Pharmacol. Physiol. 2006 33 : 857 62.
45. Mitchell EM. Obesity: Psychological aspects and management. Br. Hosp. J. Med. 1980 24 : 523 30.
46. Havel PJ. Peripheral signals conveying metabolic information to the brain: Short-term and long-term regulation of food intake and energy homeostasis. Exp. Biol. Med. 2001 226 : 963 77.
47. Bhalla RC, Toth KF, Tan E, Bhatty RA, Mathias E, Sharma RV. Vascular effects of metformin. Possible mechanisms for its antihypertensive action in the spontaneously hypertensive rat. Am. J. Hypertens. 1996 9 : 570 6.
48. Shäffers RF. Do effects on blood pressure contribute to improved clinical outcomes with metformin? Diabetes Metab. 2003 29 (Suppl 6S 62 70.
49. 2+]. J. Hypertens. 1997 15 : 269 74.
50. Viner RM, Segal TY, Lichtarowicz-Krynska E, Hindmarsh P. Prevalence of the insulin resistance syndrome in obesity. Arch. Dis. Child. 2005 90 : 10 14.
51. Wulffelé MG, Kooy A, Zeeuw D, Stehouwer CDA, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: A systematic review. J. Intern. Med. 2004 256 : 1 14.
52. Sidhu JS, Kaposzta Z, Markus HS, Kaski JC. Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler. Thromb. Vasc. Biol. 2004 24 : 930 4.
53. van Wijk JPH, Rabelink TJ. PPAR-γ agonists: Shifting attention from the belly to the heart? Arterioscler. Thromb. Vasc. Biol. 2004 24 : 798 800.
54. Hunt KJ, Williams K, Rivera D, O'Leary DH, Haffner SM, Stern MP. Elevated carotid artery intima-media thickness levels in individuals who subsequently develop type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 2003 23 : 1845 50.
55. Orio Jr. F, Palomba S, Cascella T et al. Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: Results of a 6-month study. J. Clin. Endocrinol. Metab. 2005 90 : 6072 6.
56. Zureik M, Ducimetière P, Touboul P-J et al. Common carotid intima-media thickness predicts occurrence of carotid atherosclerotic plaques. Longitudinal results from the Aging Vascular Study (EVA) Study. Arterioscler. Thromb. Vasc. Biol. 2000 20 : 1622 9.
57. O'Leary DH, Polak JF, Kornmal RA et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N. Engl. J. Med. 1999 340 : 14 22.
58. Stakos DA, Schuster DP, Sparks EA, Wooley CF, Osei K, Boudoulas H. Long term cardiovascular effects of oral antidiabetic agents in non-diabetic patients with insulin resistance: Double blind, prospective, randomised study. Heart 2005 91 : 589 94.
59. Zieman SJ, Melenovsky V, Kass DA. Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler. Thromb. Vasc. Biol. 2005 25 : 932 43.
60. Zalba G, Fortuño A, Díez J. Oxidative stress and atherosclerosis in early chronic kidney disease. Nephrol. Dial. Transplant. 2006 21 : 2686 90.
61. Radi R, Beckman JS, Bush KM, Freeman BA. Peroxynitrite-induced membrane lipid peroxidation: The cytotoxic potential of superoxide and nitric oxide. Arch. Biochem. Biophys. 1991 288 : 481 7.
62. Requena JR, Fu M-X, Ahmed MU, Jenkins AJ, Lyons TJ, Torpes S. Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions. Advanced glycation end-products in diabetes mellitus and renal failure. Nephrol. Dial. Transplant. 1996 11 (Suppl. 5 48 53.
63. Wondral GT, Cervantes-Laurean D, Roberts MJ et al. Identification of alpha-dicarbonyl scavengers for cellular protection against carbonyl stress. Biochem. Pharmacol. 2002 63 : 361 73.
64. Beisswenger N, Ruggiero-Lopez D. Metformin inhibition of glycation processes. Diabetes Metab. 2003 29 (Suppl 6S 95 103.
65. Inagi R, Miyata T. Oxidative protein damage with carbohydrates and lipids in uremia: 'Carbonyl stress'. Blood Purif. 1999 17 : 95 8.
66. Witko-Sarsat V, Friedlander M, Capeillere-Blandin C et al. Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int. 1996 49 : 1304 13.
67. Selemeci L, Seres L, Antal M, Lukacs J, Regoly-Merei A, Acsady G. Advanced oxidation protein products (AOPP) for monitoring oxidative stress in critically ill patients: A simple, fast and inexpensive automated technique. Clin. Chem. Lab. Med. 2005 43 : 294 7.
68. Petersen JS, DiBona GF. Acute sympathoinhibitory actions of metformin in spontaneously hypertensive rats. Hypertension 1996 27 : 619 25.
69. Isoda K, Young JL, Zirlik A et al. Metformin inhibits proinflammatory responses and nuclear factor-κB in human vascular wall cells. Arterioscler. Thromb. Vasc. Biol. 2006 26 : 611 17.
70. Cheng J-T, Huang C-C, Liu I-M, Tzeng TF, Chang CJ. Novel mechanism for plasma glucose-lowering action of metformin in streptozotocin-induced diabetic rats. Diabetes 2006 55 : 819 25.
71. Carter AM, Bennett CE, Bostock JA, Grant PJ. Metformin reduces C-reactive protein but not complement factor C3 in overweight patients with Type 2 diabetes mellitus. Diabet. Med. 2005 22 : 1282 4.
72. Majithiya JB, Balaraman R. Metformin reduces blood pressure and restores endothelial function in aorta of streptozotocin-induced diabetic rats. Life Sci. 2006 88 : 2615 24.
73. Gallo A, Ceolotto G, Pinton P et al. Metformin prevents glucose-induced protein kinase C-β2 activation in human umbilical vein endothelial cells through an antioxidant mechanism. Diabetes 2005 54 : 1123 31.
74. Khouri H, Collin F, Bonnefont-Rousselot D, Legrand A, Jore D, Gardès-Albert M. Radical-induced oxidation of metformin. Eur. J. Biochem. 2004 271 : 4745 52.
75. Hattori Y, Suzuki K, Hattori S, Kasai K. Metformin inhibits cytokine-induced nuclear factor κ-B activation via AMP-activated protein kinase activation in vascular endothelial cells. Hypertension 2006 47 : 1183 8.
76. De Jager J, Kooy A, Lehert P, Bets D et al. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: A randomized, placebo-controlled trial. J. Intern. Med. 2005 257 : 100 9.
77. Yonekura H, Yamamoto Y, Sakurai SW, Waranabe T, Yamamoto H. Roles of the receptor for advanced glycation endproducts in diabetes-induced vascular injury. J. Pharmacol. Sci. 2005 97 : 305 11.
78. Ruggiero-Lopez D, Lecomte M, Moinet G, Patereau G, Lagarde M, Wiernsperger N. Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. Biochem. Pharmacol. 1999 58 : 1765 73.
79. Iida KT, Kawakami Y, Suzuki M et al. Effect of thiazolidinediones and metformin on LDL oxidation and aortic endothelium relaxation in diabetic GK rats. Am. J. Physiol. Endocrinol. Metab. 2003 284 : E1125 30.